cbdMD Future Growth
Future criteria checks 1/6
cbdMD is forecast to grow earnings and revenue by 107.1% and 8.9% per annum respectively while EPS is expected to grow by 123.8% per annum.
Key information
107.1%
Earnings growth rate
123.8%
EPS growth rate
| Pharmaceuticals earnings growth | 22.8% |
| Revenue growth rate | 8.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Feb 2024 |
Recent future growth updates
Recent updates
cbdMD (NYSEMKT:YCBD) Has Debt But No Earnings; Should You Worry?
Mar 23
This Insider Has Just Sold Shares In cbdMD, Inc. (NYSEMKT:YCBD)
Feb 23If You Had Bought cbdMD (NYSEMKT:YCBD) Stock A Year Ago, You Could Pocket A 383% Gain Today
Feb 09We Wouldn't Rely On cbdMD's (NYSEMKT:YCBD) Statutory Earnings As A Guide
Jan 13Is cbdMD (NYSEMKT:YCBD) Using Debt Sensibly?
Dec 15
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2025 | 27 | -3 | N/A | N/A | 1 |
| 9/30/2024 | 23 | -7 | N/A | N/A | 1 |
| 12/31/2023 | 23 | -24 | -3 | -2 | N/A |
| 9/30/2023 | 24 | -27 | -5 | -4 | N/A |
| 6/30/2023 | 26 | -26 | -6 | -6 | N/A |
| 3/31/2023 | 29 | -56 | -8 | -8 | N/A |
| 12/31/2022 | 32 | -59 | -12 | -12 | N/A |
| 9/30/2022 | 35 | -74 | -16 | -15 | N/A |
| 6/30/2022 | 37 | -63 | -18 | -17 | N/A |
| 3/31/2022 | 39 | -29 | -20 | -20 | N/A |
| 12/31/2021 | 41 | -37 | -18 | -17 | N/A |
| 9/30/2021 | 44 | -26 | -14 | -14 | N/A |
| 6/30/2021 | 46 | -28 | -10 | -10 | N/A |
| 3/31/2021 | 46 | -38 | -6 | -7 | N/A |
| 12/31/2020 | 44 | -10 | -9 | -8 | N/A |
| 9/30/2020 | 42 | 12 | -12 | -11 | N/A |
| 6/30/2020 | 40 | 31 | -19 | -17 | N/A |
| 3/31/2020 | 37 | 15 | -23 | -20 | N/A |
| 12/31/2019 | 33 | -32 | -21 | -19 | N/A |
| 9/30/2019 | 24 | -45 | -17 | -15 | N/A |
| 6/30/2019 | 8 | -60 | -10 | -10 | N/A |
| 3/31/2019 | 3 | -35 | -7 | -6 | N/A |
| 12/31/2018 | 0 | -2 | -5 | -5 | N/A |
| 9/30/2018 | 0 | -2 | -6 | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YCBD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: YCBD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: YCBD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: YCBD's revenue (8.9% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: YCBD's revenue (8.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if YCBD's Return on Equity is forecast to be high in 3 years time